AGP Picks
View all

New Jersey Health Reporter
Provided by AGP

New Jersey Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on September 29, 2026

PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026
Sep. 29, 2026

PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026

Indeterminate GlobeNewswire
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Sep. 29, 2026

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Indeterminate GlobeNewswire
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
Sep. 29, 2026

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

Indeterminate GlobeNewswire
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
Sep. 29, 2026

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Indeterminate GlobeNewswire
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Sep. 29, 2026

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Indeterminate GlobeNewswire
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
Sep. 29, 2026

Why Weight Loss Plateaus Happen: 5 Metabolic Causes

Indeterminate GlobeNewswire
ABBYY Appoints Paula Sanders to Chief Customer Experience Officer, Providing Customers a Single, End-to-End Experience
Sep. 29, 2026

ABBYY Appoints Paula Sanders to Chief Customer Experience Officer, Providing Customers a Single, End-to-End Experience

Indeterminate GlobeNewswire
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
Sep. 29, 2026

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

Indeterminate GlobeNewswire
Cascade Prodrug Inc. Appoints Kenneth Mandell, M.D., Ph.D. to Board of Directors
Sep. 29, 2026

Cascade Prodrug Inc. Appoints Kenneth Mandell, M.D., Ph.D. to Board of Directors

Indeterminate GlobeNewswire
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Sep. 29, 2026

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Indeterminate GlobeNewswire
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Sep. 29, 2026

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Indeterminate GlobeNewswire
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Sep. 29, 2026

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

Indeterminate GlobeNewswire
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
Sep. 29, 2026

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

Indeterminate GlobeNewswire
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
Sep. 29, 2026

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

Indeterminate GlobeNewswire
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for…
Sep. 29, 2026

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for…

Indeterminate GlobeNewswire
Canada’s Coffee Industry Generates $34.7 Billion in Economic Impact
Sep. 29, 2026

Canada’s Coffee Industry Generates $34.7 Billion in Economic Impact

Indeterminate GlobeNewswire
Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation
Sep. 29, 2026

Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation

Indeterminate GlobeNewswire
4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines
Sep. 29, 2026

4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines

Indeterminate GlobeNewswire
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Sep. 29, 2026

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Indeterminate GlobeNewswire
ANJAC HEALTH & BEAUTY LAUNCHES A DEDICATED OFFERING TO SUPPORT PATIENTS ON GLP-1 TREATMENTS
Sep. 29, 2026

ANJAC HEALTH & BEAUTY LAUNCHES A DEDICATED OFFERING TO SUPPORT PATIENTS ON GLP-1 TREATMENTS

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

New Jersey Health Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.